Yann Hamon 8:00 a.m., June 14, 2022

With its Future Trophies, Europe 1 rewards companies, associations or local authorities each year for their audacity, their innovation and their visionary side.

In the running for the Health Trophy, in partnership with Arthrtitis-Clarins, MDoloris markets an innovative solution to measure the pain felt by patients who cannot verbalize it. 

MDoloris is a French start-up which was born in June 2010 in Lille.

Thirty-three years of academic research conducted by Inserm have resulted in the development of this totally innovative application, the aim of which is to measure the pain and comfort of patients, whether they are conscious or not. 

Measuring the pain of patients with cognitive disorders 

The technology used by MDoloris "is based on a physiological signal, i.e. a cardiographic signal (ECG), collected by electrodes placed on the patient's thorax. The monitor analyzes and manages a biological pain index which makes it possible to locate the pain and to affirm whether the patient is suffering or not", explains Fabien Pagniez, its president and founder.  

MDoloris is mainly used in the operating room in hospitals and clinics by anesthesiologists and resuscitators.

A technology that also makes it possible to measure the pain felt by patients with cognitive disorders, such as Alzheimer's disease or people at the end of life, unable to communicate.

A real step forward in the management of the suffering of patients. 

MDoloris, a proven technology 

With more than 4,000 MDoloris monitors distributed in more than 76 countries around the world and more than 200 international publications attesting to its reliability, MDoloris tries to go further by offering a new technology based on an intelligent textile.

This will make it possible to obtain, in real time, the patient's level of comfort.

The data will be accessible on smartphone, wherever you are in the world as long as you have internet access.

A solution that Fabien Pagniez hopes to be able to market from the summer of 2023.